| Sector |
Trading
|
Compare with Sector peers |
| Industry |
Trading
|
Compare with Industry peers |
| Website | https://www.vivanzabiosciences.com/ | |
| Market Cap | 75.60 Cr. | |
| Enterprise Value(EV) | 78.53 Cr. | 2021-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 1.01 | Trailing Twelve Months Ending 2021-12 |
| Price-Earning Ratio (PE) | 187.13 | Trailing Twelve Months Ending 2021-12 |
| Industry PE | 114.81 | Trailing Twelve Months Ending 2021-12 |
| Book Value / Share | 9.23 | Trailing Twelve Months Ending 2021-12 |
| Price to Book Value | 20.48 | Calculated using Price: 189.00 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 0.40 Cr. | 4,000,000 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Head quartered in Gujarat, Vivanza Biosciences Limited came into existence in April 2016 with the sole aim to further spread its wings in global market with global quality pharmaceutical products at competitive pricing system. It is the bridge between people, Medical Practitioners and the Patients and together it is a healthcare organization dedicated to improving the lives of people globally. Business area of the company The company is engaged in the business of business of Pharmaceutical Products. Products
|
||
Company Profile
Head quartered in Gujarat, Vivanza Biosciences Limited came into existence in April 2016 with the sole aim to further spread its wings in global market with global quality pharmaceutical products at competitive pricing system. It is the bridge between people, Medical Practitioners and the Patients and together it is a healthcare organization dedicated to improving the lives of people globally.
Business area of the company
The company is engaged in the business of business of Pharmaceutical Products.
Products
| 1 Day |
|
|
| 1 Week |
|
|
| 1 Month |
|
+1.07% |
| 3 Month |
|
+23.57% |
| 6 Month |
|
-0.29% |
| 1 Year |
|
+165.64% |
| 2 Year |
|
+1342.75% |
| 5 Year |
|
+7.54% |
| 10 Year |
|
| 6 years | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | -242.60 | -17.54 | 5.66 | -12.56 | -6.46 | 2.41 | |
| Return on Capital Employed (%) | -11.38 | -10.82 | 12.73 | -0.40 | 5.74 | 17.11 | |
| Return on Assets (%) | -9.49 | -7.99 | 2.37 | -4.15 | -1.75 | 0.72 |
| Particulars | 7 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
| Shh. Funds | 0 | 4 | 4 | 3 | 3 | 3 | 4 | |
| Non Curr. Liab. | 0 | 1 | 1 | 0 | 3 | |||
| Curr. Liab. | 1 | 3 | 6 | 7 | 9 | 5 | 3 | |
| Minority Int. | ||||||||
| Equity & Liab. | 1 | 7 | 10 | 11 | 12 | 8 | 10 | |
| Non Curr. Assets | 1 | 3 | 3 | 3 | 3 | 3 | 3 | |
| Curr. Assets | 0 | 4 | 7 | 8 | 9 | 5 | 7 | |
| Misc. Exp. not W/O | ||||||||
| Total Assets | 1 | 7 | 10 | 11 | 12 | 8 | 10 |
| Particulars | 7 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
| Net Sales | 3 | 6 | 3 | 10 | 10 | 7 | ||
| Other Income | 0 | 1 | 1 | 1 | ||||
| Total Income | 4 | 6 | 3 | 10 | 10 | 8 | ||
| Total Expenditure | 0 | -4 | -6 | -3 | -10 | -10 | -8 | |
| PBIDT | 0 | 0 | 1 | 0 | 0 | 1 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Depreciation | 0 | 0 | ||||||
| Taxation | 0 | 0 | 0 | |||||
| Exceptional Items | ||||||||
| PAT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Minority Interest | ||||||||
| Share Associate | ||||||||
| Other Related Items | ||||||||
| Consolidated Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Adjusted EPS | -3 | -1 | 1 | -1 | -1 | 0 | 1 |
| Particulars | 6 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | -2 | 0 | 1 | 3 | -3 | ||
| Cash Fr. Inv. | 2 | 0 | |||||
| Cash Fr. Finan. | 0 | -1 | -1 | -3 | 2 | ||
| Net Change | 0 | -1 | 0 | 0 | 0 | ||
| Cash & Cash Eqvt | -2 | -3 | -3 | -3 | -3 |
|
Wed, 18 May 2022
Board Meeting Intimation for Board Meeting Intimation For Notice Of Board Meeting Pursuant To Regulation 29(1) Of SEBI LODR Regulations 2015 Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 inter alia to consider and approve 1) To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the Quarter ended 31st March 2022 ;2) To consider Preferential Issue of Warrants.3) To Increase the Authorised Share Capital of the Company from Rs. 4.00 Crore to Rs. 9.00 Crore.4) To change the Clause V- Authorised Capital of Memorandum of Association (MOA) of the Company;5) To consider the Termination of existing Company Secretary and to Appoint the new Company Secretary and Compliance Officer of the Company.6) To invest in the Vitaanova Healthcare Uganda Limited a Company incorporated in Uganda. 7) To Appoint the Statutory Auditor of the Company. 8) To consider and approve the notice of Annual General Meeting to seek approval for the above mentioned items as recommended by the Board.9) Any other business as Board deem fit to discuss with the permission of the Chair. |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Sat, 30 Apr 2022
Compliance Certificate By PCS For Half Year Ended 31/03/2022 Compliance Certificate under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the half year ended on 31st March 2022. |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Fri, 29 Apr 2022
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.
Date: 29/04/2022 |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
No Scans Found |
Equities
M.F.
Sectors